Nicholas Piramal India Inks R&D Deal With Merck
This article was originally published in The Pink Sheet Daily
Executive Summary
Mumbai-based Nicholas Piramal will develop two oncology targets for Merck and stands to receive up to $175 million per target plus royalties.
You may also be interested in...
Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.
Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.
Lilly and Merck Lead the Way With Asian FIPNet Strategies
There's a new acronym to learn:FIPNet--for fully integrated pharmaceutical network. Nowhere is the strategy more apparent than in Asia, where Big Pharma hopes to tap into the increasingly high quality research available in India and China--countries that also should prove to be a major source of future customers. Merck and Eli Lilly are two companies leading the FIPNet charge.